

**TechStart Grant Awardees**  
**May 2, 2012 Application Deadline**  
**100 Word Non-Confidential Project Summaries**

*All awardees will be contacted by MTI within 5 business days.*

TS0103 – Colon Cancer Risk Assessment Development

*Bar Harbor Biotechnology*

Colorectal cancer (CRC) is the third most common cancer worldwide and affects over one million people in North America Alone. Five year survival rates are 90% with an early diagnosis but plummet to 6% for Stage IV patients. Unfortunately, only 39% of cases are found at the early stage

Bar Harbor Biotechnology (BRB) has developed a new approach to early detection. Our test increases the chances of early detection thereby raise the patient's chance of survival. MTI TechStart funding will allow BHB to pursue federal funding to bring this exciting new risk assessment tool to market.

Award: \$5,000

Match: \$5,000

Biotechnology